Symbols / ROIV
ROIV Chart
About
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 20.23B |
| Enterprise Value | 16.51B | Income | -809.24M | Sales | 13.31M |
| Book/sh | 6.02 | Cash/sh | 6.33 | Dividend Yield | — |
| Payout | 0.00% | Employees | 750 | IPO | — |
| P/E | — | Forward P/E | -22.58 | PEG | — |
| P/S | 1519.59 | P/B | 4.70 | P/C | — |
| EV/EBITDA | -13.06 | EV/Sales | 1240.39 | Quick Ratio | 29.81 |
| Current Ratio | 30.66 | Debt/Eq | 2.19 | LT Debt/Eq | — |
| EPS (ttm) | -1.17 | EPS next Y | -1.25 | EPS Growth | — |
| Revenue Growth | -77.80% | Earnings | 2026-02-06 | ROA | -14.47% |
| ROE | -19.14% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -169.65% | Profit Margin | 0.00% | Shs Outstand | 715.70M |
| Shs Float | 540.98M | Short Float | 4.35% | Short Ratio | 4.12 |
| Short Interest | — | 52W High | 28.29 | 52W Low | 8.73 |
| Beta | 1.23 | Avg Volume | 7.17M | Volume | 5.57M |
| Target Price | $31.73 | Recom | Strong_buy | Prev Close | $27.76 |
| Price | $28.26 | Change | 1.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$31.73
Mean price target
2. Current target
$28.26
Latest analyst target
3. DCF / Fair value
$-8.41
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.26
Low
$22.00
High
$38.00
Mean
$31.73
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | main | Citigroup | Buy → Buy | $35 |
| 2026-02-10 | main | HC Wainwright & Co. | Buy → Buy | $33 |
| 2026-02-09 | main | Guggenheim | Buy → Buy | $30 |
| 2025-12-15 | main | Leerink Partners | Outperform → Outperform | $32 |
| 2025-12-15 | main | Goldman Sachs | Buy → Buy | $33 |
| 2025-12-12 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-11-11 | main | Citigroup | Buy → Buy | $26 |
| 2025-10-29 | main | Citigroup | Buy → Buy | $25 |
| 2025-09-18 | main | Goldman Sachs | Buy → Buy | $24 |
| 2025-09-18 | main | Jefferies | Buy → Buy | $20 |
| 2025-09-18 | main | JP Morgan | Overweight → Overweight | $20 |
| 2025-09-18 | main | Guggenheim | Buy → Buy | $21 |
| 2025-09-18 | main | Leerink Partners | Outperform → Outperform | $22 |
| 2025-09-18 | main | B of A Securities | Neutral → Neutral | $17 |
| 2025-09-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-09-02 | init | Citigroup | — → Buy | $16 |
| 2025-06-18 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-05-28 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-04-21 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-02-11 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
- Insider Sale: President and Vant Chair of $ROIV Sells 1,400,000 Shares - Quiver Quantitative ue, 24 Feb 2026 01
- Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? - Yahoo Finance ue, 04 Nov 2025 08
- Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha Fri, 06 Feb 2026 08
- Roivant’s brepocitinib delivers rapid, sustained remissions in cutaneous sarcoidosis — first positive placebo-controlled trial - Stock Titan Fri, 06 Feb 2026 08
- Roivant Sciences Ltd. (ROIV) Investor Outlook: Analyzing Its 16.86% Potential Upside - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- A Look At Roivant Sciences (ROIV) Valuation After PHocus Trial Milestone And Weak Quarterly Earnings - Sahm Wed, 18 Feb 2026 08
- Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq Fri, 06 Feb 2026 08
- Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st Sat, 07 Feb 2026 08
- $ROIV stock is up 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 06 Feb 2026 08
- Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum - Yahoo Finance Sun, 08 Feb 2026 08
- Priovant pill sharply improves disfiguring skin sarcoidosis in Phase 2 - Stock Titan Fri, 06 Feb 2026 08
- Roivant Sciences (ROIV): Evaluating Valuation After Strong Share Price Momentum in Biotech - Yahoo Finance Wed, 29 Oct 2025 07
- New Analyst Forecast: $ROIV Given $35 Price Target - Quiver Quantitative ue, 10 Feb 2026 08
- Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data - Yahoo Finance Fri, 13 Feb 2026 08
- Insider Sale: Director at $ROIV Sells 432,718 Shares - Quiver Quantitative Fri, 19 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3000000 | 82039460.0 | — | Sale at price 27.15 - 27.51 per share. | TORTI FRANK M | Officer | — | 2026-02-23 00:00:00 | D |
| 1 | 3000000 | 11550000.0 | — | Conversion of Exercise of derivative security at price 3.85 per share. | TORTI FRANK M | Officer | — | 2026-02-23 00:00:00 | D |
| 2 | 200000 | 5298000.0 | — | Sale at price 26.49 per share. | VENKER ERIC | Officer | — | 2026-02-13 00:00:00 | D |
| 3 | 200000 | 770000.0 | — | Conversion of Exercise of derivative security at price 3.85 per share. | VENKER ERIC | Officer | — | 2026-02-13 00:00:00 | D |
| 4 | 1225784 | 32658518.0 | — | Sale at price 26.49 - 26.76 per share. | GOLD DANIEL ALLEN | Director | — | 2026-02-13 00:00:00 | I |
| 5 | 1225784 | 32658518.0 | — | Sale at price 26.49 - 26.76 per share. | MANCHESTER KEITH S | Director | — | 2026-02-13 00:00:00 | I |
| 6 | 339441 | 8985003.0 | — | Sale at price 26.47 per share. | SUKHATME MAYUKH | President | — | 2026-02-09 00:00:00 | D |
| 7 | 651558 | 8261755.0 | — | Conversion of Exercise of derivative security at price 12.68 per share. | SUKHATME MAYUKH | President | — | 2026-02-09 00:00:00 | D |
| 8 | 609 | — | — | Stock Award(Grant) at price 0.00 per share. | MOMTAZEE JAMES C | Director | — | 2026-01-20 00:00:00 | D |
| 9 | 1164 | — | — | Stock Award(Grant) at price 0.00 per share. | OREN ILAN | Director | — | 2026-01-20 00:00:00 | D |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 42.17M | 24.94M | -16.96M | 54.74M |
| TaxRateForCalcs | 0.25 | 0.00 | 0.19 | 0.19 |
| NormalizedEBITDA | -1.27B | -6.11B | -700.87M | -1.20B |
| TotalUnusualItems | 168.68M | 5.31B | -89.29M | 288.08M |
| TotalUnusualItemsExcludingGoodwill | 168.68M | 5.31B | -89.29M | 288.08M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -545.01M | 4.66B | -782.64M | -845.26M |
| ReconciledDepreciation | 14.07M | 22.04M | 18.86M | 5.93M |
| ReconciledCostOfRevenue | 911.00K | 1.60M | 3.03M | 8.97M |
| EBITDA | -1.10B | -802.89M | -790.16M | -910.77M |
| EBIT | -1.11B | -824.93M | -809.01M | -916.71M |
| NetInterestIncome | 258.38M | 146.43M | 32.18M | -6.67M |
| InterestExpense | 34.78M | 27.97M | 7.04M | 2.81M |
| InterestIncome | 258.38M | 146.43M | 32.18M | 369.00K |
| NormalizedIncome | -671.52M | -617.74M | -710.32M | -1.08B |
| NetIncomeFromContinuingAndDiscontinuedOperation | -171.98M | 4.35B | -1.01B | -845.26M |
| TotalExpenses | 1.14B | 857.64M | 840.54M | 1.27B |
| TotalOperatingIncomeAsReported | -1.00B | 4.50B | -906.76M | -1.35B |
| DilutedAverageShares | 725.40M | 831.05M | 712.79M | 669.75M |
| BasicAverageShares | 725.40M | 783.25M | 712.79M | 669.75M |
| DilutedEPS | -0.24 | 5.23 | -1.42 | -1.26 |
| BasicEPS | -0.24 | 5.23 | -1.42 | -1.26 |
| DilutedNIAvailtoComStockholders | -171.98M | 4.35B | -1.01B | -845.26M |
| NetIncomeCommonStockholders | -171.98M | 4.35B | -1.01B | -845.26M |
| NetIncome | -171.98M | 4.35B | -1.01B | -845.26M |
| MinorityInterests | 184.75M | 117.72M | 106.43M | 78.85M |
| NetIncomeIncludingNoncontrollingInterests | -356.73M | 4.23B | -1.12B | -924.12M |
| NetIncomeDiscontinuousOperations | 373.03M | -315.15M | -226.39M | 0.00 |
| NetIncomeContinuousOperations | -729.76M | 4.55B | -889.07M | -924.12M |
| TaxProvision | 48.17M | 21.50M | 4.08M | 369.00K |
| PretaxIncome | -681.59M | 4.57B | -884.99M | -923.75M |
| OtherIncomeExpense | 173.72M | 5.25B | -108.16M | 294.67M |
| OtherNonOperatingIncomeExpenses | 5.04M | -60.40M | -18.87M | 6.59M |
| SpecialIncomeCharges | 113.50M | 5.35B | -68.47M | -68.38M |
| GainOnSaleOfBusiness | 113.50M | 5.38B | 29.28M | 5.04M |
| OtherSpecialCharges | 26.45M | 97.75M | 73.42M | 596.13M |
| RestructuringAndMergernAcquisition | 26.45M | 97.75M | 139.89M | 596.13M |
| EarningsFromEquityInterest | 0.00 | -3.75M | ||
| GainOnSaleOfSecurity | 55.19M | -47.97M | -20.82M | 356.46M |
| NetNonOperatingInterestIncomeExpense | 258.38M | 146.43M | 32.18M | -6.67M |
| InterestExpenseNonOperating | 34.78M | 27.97M | 7.04M | 2.81M |
| InterestIncomeNonOperating | 258.38M | 146.43M | 32.18M | 369.00K |
| OperatingIncome | -1.11B | -824.93M | -809.01M | -1.21B |
| OperatingExpense | 1.14B | 856.04M | 837.51M | 1.26B |
| ResearchAndDevelopment | 550.41M | 439.91M | 454.06M | 483.04M |
| SellingGeneralAndAdministration | 591.41M | 416.13M | 383.45M | 775.03M |
| GeneralAndAdministrativeExpense | 591.41M | 416.13M | 383.45M | 775.03M |
| OtherGandA | 591.41M | 416.13M | 383.45M | 775.03M |
| GrossProfit | 28.14M | 31.11M | 28.50M | 46.32M |
| CostOfRevenue | 911.00K | 1.60M | 3.03M | 8.97M |
| TotalRevenue | 29.05M | 32.71M | 31.53M | 55.29M |
| OperatingRevenue | 29.05M | 32.71M | 31.53M | 55.29M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 695.94M | 806.68M | 760.14M | 694.98M |
| ShareIssued | 695.94M | 806.68M | 760.14M | 694.98M |
| TotalDebt | 100.17M | 53.99M | 481.40M | 283.89M |
| TangibleBookValue | 4.69B | 5.97B | 1.01B | 1.66B |
| InvestedCapital | 4.69B | 5.97B | 1.57B | 1.87B |
| WorkingCapital | 4.85B | 6.47B | 1.53B | 1.96B |
| NetTangibleAssets | 4.69B | 5.97B | 1.01B | 1.66B |
| CapitalLeaseObligations | 100.17M | 53.99M | 65.17M | 73.87M |
| CommonStockEquity | 4.69B | 5.97B | 1.16B | 1.66B |
| TotalCapitalization | 4.69B | 5.97B | 1.53B | 1.87B |
| TotalEquityGrossMinorityInterest | 5.19B | 6.45B | 1.61B | 2.06B |
| MinorityInterest | 499.59M | 479.95M | 449.82M | 404.49M |
| StockholdersEquity | 4.69B | 5.97B | 1.16B | 1.66B |
| OtherEquityInterest | -100.00M | |||
| GainsLossesNotAffectingRetainedEarnings | 9.44M | -4.08M | -2.62M | -946.00K |
| OtherEquityAdjustments | 9.44M | -4.08M | -2.62M | -946.00K |
| RetainedEarnings | 116.06M | 576.17M | -3.77B | -2.76B |
| AdditionalPaidInCapital | 4.56B | 5.40B | 4.93B | 4.42B |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 249.74M | 773.95M | 782.02M | 523.70M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 100.33M | 507.19M | 509.57M | 339.33M |
| OtherNonCurrentLiabilities | 10.00M | 28.23M | 80.58M | 66.83M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 433.94M | ||
| NonCurrentDeferredLiabilities | 13.74M | 0.00 | ||
| NonCurrentDeferredRevenue | 13.74M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 90.33M | 45.02M | 428.99M | 272.49M |
| LongTermCapitalLeaseObligation | 90.33M | 45.02M | 53.48M | 62.47M |
| LongTermDebt | 430.59M | 375.51M | 210.03M | 170.28M |
| CurrentLiabilities | 149.41M | 266.76M | 272.45M | 184.37M |
| OtherCurrentLiabilities | 110.41M | 2.09M | 10.86M | 3.24M |
| CurrentDeferredLiabilities | 1.17M | 4.17M | 12.44M | 10.15M |
| CurrentDeferredRevenue | 1.17M | 4.17M | 12.44M | 10.15M |
| CurrentDebtAndCapitalLeaseObligation | 9.84M | 8.97M | 52.41M | 11.40M |
| CurrentCapitalLeaseObligation | 9.84M | 8.97M | 11.69M | 11.40M |
| CurrentDebt | 12.00M | 40.72M | ||
| OtherCurrentBorrowings | 12.00M | 40.72M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 53.93M | 49.89M | 55.19M | 44.26M |
| CurrentProvisions | 23.28M | 17.57M | ||
| PayablesAndAccruedExpenses | 84.47M | 93.33M | 132.75M | 118.56M |
| CurrentAccruedExpenses | 60.37M | 69.53M | 94.37M | 83.27M |
| Payables | 24.11M | 23.80M | 38.37M | 35.29M |
| TotalTaxPayable | 416.00K | 9.77M | 542.00K | 708.00K |
| IncomeTaxPayable | 416.00K | 9.77M | 542.00K | 708.00K |
| AccountsPayable | 23.69M | 14.03M | 37.83M | 34.58M |
| TotalAssets | 5.44B | 7.22B | 2.39B | 2.59B |
| TotalNonCurrentAssets | 436.88M | 490.65M | 591.02M | 438.61M |
| OtherNonCurrentAssets | 32.86M | 183.58M | 49.48M | 25.82M |
| InvestmentsAndAdvances | 302.94M | 247.75M | 304.32M | 325.83M |
| OtherInvestments | 302.94M | 247.75M | 304.32M | 325.83M |
| GoodwillAndOtherIntangibleAssets | 137.84M | 144.88M | 0.00 | |
| NetPPE | 101.08M | 59.32M | 92.34M | 86.95M |
| GrossPPE | 101.08M | 59.32M | 92.34M | 86.95M |
| OtherProperties | 101.08M | 59.32M | 92.34M | 86.95M |
| CurrentAssets | 5.00B | 6.73B | 1.80B | 2.15B |
| OtherCurrentAssets | 113.17M | 80.61M | 15.53M | 22.12M |
| AssetsHeldForSaleCurrent | 0.00 | 156.27M | ||
| RestrictedCash | 5.37M | 5.01M | 3.90M | 77.70M |
| PrepaidAssets | 55.10M | 60.83M | 53.37M | |
| Inventory | 35.25M | 2.76M | 0.00 | |
| Receivables | 82.81M | 37.64M | 6.73M | |
| TaxesReceivable | 1.83M | 2.36M | 2.85M | |
| AccruedInterestReceivable | 27.44M | 4.91M | ||
| AccountsReceivable | 53.55M | 30.38M | 3.88M | |
| CashCashEquivalentsAndShortTermInvestments | 4.89B | 6.49B | 1.68B | 2.06B |
| OtherShortTermInvestments | 2.17B | 0.00 | ||
| CashAndCashEquivalents | 2.72B | 6.49B | 1.68B | 2.06B |
| CashEquivalents | 2.62B | 6.31B | ||
| CashFinancial | 93.95M | 182.66M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -844.05M | -766.65M | -856.08M | -695.16M |
| RepurchaseOfCapitalStock | -1.29B | 0.00 | 0.00 | |
| RepaymentOfDebt | -52.75M | -30.70M | -30.14M | -21.59M |
| IssuanceOfDebt | 0.00 | 0.00 | 159.90M | 36.40M |
| IssuanceOfCapitalStock | 112.78M | 438.56M | 379.71M | 0.00 |
| CapitalExpenditure | -4.60M | -1.38M | -12.69M | -17.44M |
| InterestPaidSupplementalData | 5.96M | 10.27M | 5.30M | 5.54M |
| IncomeTaxPaidSupplementalData | 61.91M | 12.35M | 5.13M | 916.00K |
| EndCashPosition | 2.73B | 6.55B | 1.69B | 2.07B |
| BeginningCashPosition | 6.55B | 1.69B | 2.07B | 2.14B |
| EffectOfExchangeRateChanges | 747.00K | 616.00K | 6.28M | 0.00 |
| ChangesInCash | -3.83B | 4.86B | -388.20M | -67.64M |
| FinancingCashFlow | -1.22B | 419.36M | 499.46M | 306.79M |
| CashFlowFromContinuingFinancingActivities | -1.22B | 419.36M | 499.46M | 306.79M |
| NetOtherFinancingCharges | -37.22M | -43.72M | -13.13M | 191.57M |
| ProceedsFromStockOptionExercised | 50.62M | 55.23M | 3.13M | 100.41M |
| NetCommonStockIssuance | -1.18B | 438.56M | 379.71M | 0.00 |
| CommonStockPayments | -1.29B | 0.00 | 0.00 | |
| CommonStockIssuance | 112.78M | 438.56M | 379.71M | 0.00 |
| NetIssuancePaymentsOfDebt | -52.75M | -30.70M | 129.75M | 14.81M |
| NetLongTermDebtIssuance | -52.75M | -30.70M | 129.75M | 14.81M |
| LongTermDebtPayments | -52.75M | -30.70M | -30.14M | -21.59M |
| LongTermDebtIssuance | 0.00 | 0.00 | 159.90M | 36.40M |
| InvestingCashFlow | -1.77B | 5.20B | -44.27M | 303.30M |
| CashFlowFromContinuingInvestingActivities | -1.77B | 5.20B | -44.27M | 303.30M |
| NetOtherInvestingChanges | 110.47M | 5.24B | -139.43M | 600.00K |
| NetInvestmentPurchaseAndSale | -2.10B | 0.00 | 0.00 | 320.17M |
| SaleOfInvestment | 1.96B | 0.00 | 0.00 | 320.17M |
| PurchaseOfInvestment | -4.06B | 0.00 | 0.00 | |
| NetBusinessPurchaseAndSale | 229.36M | -36.98M | 107.86M | -39.00K |
| SaleOfBusiness | 260.59M | 47.50M | 114.56M | 0.00 |
| PurchaseOfBusiness | -31.22M | -84.48M | -6.71M | -39.00K |
| NetPPEPurchaseAndSale | -4.60M | -1.38M | -12.69M | -17.44M |
| PurchaseOfPPE | -4.60M | -1.38M | -12.69M | -17.44M |
| OperatingCashFlow | -839.45M | -765.27M | -843.39M | -677.73M |
| CashFlowFromContinuingOperatingActivities | -839.45M | -765.27M | -843.39M | -677.73M |
| ChangeInWorkingCapital | -77.05M | 19.04M | 6.34M | 15.72M |
| ChangeInOtherWorkingCapital | 3.30M | -15.41M | 64.46M | |
| ChangeInOtherCurrentLiabilities | -14.98M | -786.00K | -6.46M | -6.87M |
| ChangeInOtherCurrentAssets | -33.83M | -64.99M | -49.09M | -28.00M |
| ChangeInPayablesAndAccruedExpense | -28.24M | 84.81M | 61.89M | 66.00M |
| ChangeInAccruedExpense | -10.07M | 62.13M | 57.53M | 50.59M |
| ChangeInInterestPayable | 0.00 | 21.98M | 18.57M | |
| ChangeInPayable | -18.17M | 22.68M | 4.36M | 15.40M |
| ChangeInAccountPayable | -18.17M | 22.68M | 4.36M | 15.40M |
| OtherNonCashItems | -102.47M | 96.04M | 37.55M | 82.76M |
| StockBasedCompensation | 289.03M | 199.63M | 217.78M | 564.96M |
| UnrealizedGainLossOnInvestmentSecurities | -55.19M | 47.97M | 20.82M | 87.29M |
| AmortizationOfSecurities | -69.96M | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 14.07M | 22.04M | 18.86M | 5.93M |
| DepreciationAndAmortization | 14.07M | 22.04M | 18.86M | 5.93M |
| OperatingGainsLosses | -481.15M | -5.38B | -29.28M | -510.27M |
| EarningsLossesFromEquityInvestments | 0.00 | 3.75M | ||
| GainLossOnInvestmentSecurities | -505.23M | |||
| GainLossOnSaleOfBusiness | -379.61M | -32.77M | -29.28M | -5.04M |
| NetIncomeFromContinuingOperations | -356.73M | 4.23B | -1.12B | -924.12M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ROIV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|